Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Capital Expenditures (2016 - 2024)

Lipocine (LPCN) has disclosed Capital Expenditures for 7 consecutive years, with $10019.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures rose 9.29% year-over-year to $10019.0, compared with a TTM value of $19186.0 through Dec 2024, up 45.71%, and an annual FY2024 reading of $90086.0, up 584.18% over the prior year.
  • Capital Expenditures was $10019.0 for Q4 2024 at Lipocine, up from $9167.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $96732.0 in Q4 2022 and bottomed at $4000.0 in Q1 2023.
  • Average Capital Expenditures over 3 years is $26169.5, with a median of $10160.5 recorded in 2022.
  • The sharpest move saw Capital Expenditures plummeted 90.52% in 2023, then rose 9.29% in 2024.
  • Year by year, Capital Expenditures stood at $96732.0 in 2022, then tumbled by 90.52% to $9167.0 in 2023, then rose by 9.29% to $10019.0 in 2024.
  • Business Quant data shows Capital Expenditures for LPCN at $10019.0 in Q4 2024, $9167.0 in Q4 2023, and $4000.0 in Q1 2023.